Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin

Tim Heise, Christian Weyer, Andreas Serwas, Sebastian Heinrichs, Johannes Osinga, Paris Roach, Jim Woodworth, Uwe Gudat, Lutz Heinemann

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

OBJECTIVE - To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS - In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 ± 2 years (mean ± SD), whose BMI was 23.0 ± 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid- mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration. RESULTS - Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after rejection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern. CONCLUSIONS - This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.

Original languageEnglish (US)
Pages (from-to)800-803
Number of pages4
JournalDiabetes Care
Volume21
Issue number5
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Insulin Lispro
Insulin
Glucose Clamp Technique
Subcutaneous Injections
Biphasic Insulins
Short-Acting Insulin
Protamines
Area Under Curve
neutral protamine lispro
Healthy Volunteers
Research Design
Pharmacokinetics
Glucose
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Heise, T., Weyer, C., Serwas, A., Heinrichs, S., Osinga, J., Roach, P., ... Heinemann, L. (1998). Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care, 21(5), 800-803. https://doi.org/10.2337/diacare.21.5.800

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. / Heise, Tim; Weyer, Christian; Serwas, Andreas; Heinrichs, Sebastian; Osinga, Johannes; Roach, Paris; Woodworth, Jim; Gudat, Uwe; Heinemann, Lutz.

In: Diabetes Care, Vol. 21, No. 5, 1998, p. 800-803.

Research output: Contribution to journalArticle

Heise, T, Weyer, C, Serwas, A, Heinrichs, S, Osinga, J, Roach, P, Woodworth, J, Gudat, U & Heinemann, L 1998, 'Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin', Diabetes Care, vol. 21, no. 5, pp. 800-803. https://doi.org/10.2337/diacare.21.5.800
Heise, Tim ; Weyer, Christian ; Serwas, Andreas ; Heinrichs, Sebastian ; Osinga, Johannes ; Roach, Paris ; Woodworth, Jim ; Gudat, Uwe ; Heinemann, Lutz. / Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. In: Diabetes Care. 1998 ; Vol. 21, No. 5. pp. 800-803.
@article{ea77ca283c8941e8b065f0c05b4e646c,
title = "Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin",
abstract = "OBJECTIVE - To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS - In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 ± 2 years (mean ± SD), whose BMI was 23.0 ± 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid- mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration. RESULTS - Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after rejection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern. CONCLUSIONS - This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.",
author = "Tim Heise and Christian Weyer and Andreas Serwas and Sebastian Heinrichs and Johannes Osinga and Paris Roach and Jim Woodworth and Uwe Gudat and Lutz Heinemann",
year = "1998",
doi = "10.2337/diacare.21.5.800",
language = "English (US)",
volume = "21",
pages = "800--803",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin

AU - Heise, Tim

AU - Weyer, Christian

AU - Serwas, Andreas

AU - Heinrichs, Sebastian

AU - Osinga, Johannes

AU - Roach, Paris

AU - Woodworth, Jim

AU - Gudat, Uwe

AU - Heinemann, Lutz

PY - 1998

Y1 - 1998

N2 - OBJECTIVE - To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS - In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 ± 2 years (mean ± SD), whose BMI was 23.0 ± 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid- mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration. RESULTS - Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after rejection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern. CONCLUSIONS - This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.

AB - OBJECTIVE - To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS - In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 ± 2 years (mean ± SD), whose BMI was 23.0 ± 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid- mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration. RESULTS - Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after rejection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern. CONCLUSIONS - This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.

UR - http://www.scopus.com/inward/record.url?scp=0031736143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031736143&partnerID=8YFLogxK

U2 - 10.2337/diacare.21.5.800

DO - 10.2337/diacare.21.5.800

M3 - Article

VL - 21

SP - 800

EP - 803

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -